Washington – Representative of a pharmaceutical industry says that Canada’s possibility is not the main goal of the threat to put 200 percent tariffs on US President Donald Trump’s pharmaceutical imports – but his plan can still disturb some parts of the Canadian region.
Jim Kane, president of the Canadian Generic Pharmaceutical Association, says there is a risk that Canada will be stuck in a crossfire as Trump pushes to reduce Americans dependence on drugs imported from places like China and India.
On Tuesday, Trump flew the idea of a large -scale pharmaceutical tariff, but said that he would give drug manufacturers a drug manufacturer of up to one and a half years before starting duties.
Keon says
But without access to the US market, they say, it may not be practical for some Canadian companies to continue production of some common drugs for the domestic market.
Keon says that the economic and security agreement between Canada and the United States is expected to ensure that the pharmaceuticals remain tariff-free.
This report of Canadian Press was first published on 9 July 2025.
Kelly Geraldin Malon, Canadian Press